Axicabtagene ciloleucel 40million-200million cells/68ml dispersion for infusion bags
NHS hospitals in England used £61,699,220 of indicative cost of Axicabtagene ciloleucel 40million-200million cells/68ml dispersion for infusion bags in the 12 months to July 2026, about 0.2% of all hospital medicines spend. That is down 20.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Axicabtagene ciloleucel 40million-200million cells/68ml dispersion for infusion bags: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Axicabtagene ciloleucel 40million-200million cells/68ml dispersion for infusion bags most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Univ Hpl B/Ham Nhs Foundation Trust | £8,413,530 |
| King's College Hpl Nhs Foundation Trust | £5,609,020 |
| University College London Foundation Tr | £5,048,118 |
| Oxford University Hospitals Nhs Ft | £4,767,667 |
| The Royal Marsden Nhs Foundation Trust | £4,487,216 |
| Cambridge Univ Hosp Nhs Foundation Trust | £4,206,765 |
| The Clatterbridge Cancer Centre Nhs Ft | £4,206,765 |
| Barts Health Nhs Trust | £3,645,863 |
| Manchester University Nhs Ft | £3,365,412 |
| University Hospital Southampton Nhs Ft | £3,084,961 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.